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The constitutive proliferation and resistance to diﬀerentiation and apoptosis of neoplastic cervical cells depend on sustained
expression of humanpapillomavirus oncogenes.Inhibition of these oncogenes is a goal for the prevention of progression of HPV-
induced neoplasiasto cervical cancer. SiHa cervical cancer cells were transfected with an HPV-16 promoter reporter construct and
treated with leukemia inhibitory factor (LIF), a human cytokine of the interleukin 6 superfamily. SiHa and CaSki cervical cancer
cells were also assessed for proliferation by MTT precipitation, programmed cell death by ﬂow cytometry, and HPV E6 and E7
expression by real-time PCR. LIF-treated cervical cancer cells showed signiﬁcantlyreduced HPV LCR activation, reduced levels of
E6 andE7 mRNA, and reduced proliferation.We report the novel use ofLIF to inhibitviral oncogeneexpression in cervical cancer
cells, with concomitantreduction in proliferation suggesting re-engagement of cell-cycle regulation.
1.Introduction
Human Papillomavirus (HPV) is a necessary causative
agent for cervical cancer [1, 2], the second most common
cancer in women [3]a n dt h i r do v e r a l lc a u s eo fc a n c e r
mortality worldwide [4]. HPV has also been detected in anal
cancer [5], cancers of the head and neck, particularly the
oropharynx and larynx [5, 6], and there is evidence that
some breast cancers contain HPV genomes [7]. At present,
no approved, eﬀective nonsurgical intervention for cervical
dysplasia or for the underlying HPV infection exists. For
localized and advanced localized cervical carcinoma, the
concurrent administration of chemotherapy and radiation
has been successful, if signiﬁcantly toxic, but the treatment
of recurrent and metastatic disease remains a challenge.
For metastatic cervical cancer, standard chemotherapy is
generally palliative rather than curative, and there is limited
experience with biologicsin this group of patients; therefore,
a new treatment modality isclearly needed.With over13,000
cases of invasive cervical cancer, 50,000 cases of carcinoma
in situ, and as many as 1,000,00 cases of cervical dysplasia
diagnosed each year in the US alone, and with the majority
of spending going to followup and treatment of neoplasia,
a noninvasive treatment would have a tremendous eﬀect on
both women’s health and the ﬁnancial burden of HPV.
The expression of the viral gene products E6 and E7,
regulated by the viral long control region (LCR), is also
predictive of progression toward cancer: higher levels of
viral mRNA correlate with higher-grade lesions [8]. E6 [9]
and E7 [9, 10]h a v ea l s ob e e ns h o w nt oc o n t r i b u t et o
the invasiveness and metastatic aggressiveness [10, 11]o f
transformed cells, and the targeted inhibition by 50%–90%
in vitro of HPV oncoproteins (using siRNA [12], peptide
aptamers [13],or a transfected E2 gene [14]) typicallyresults
in p53 reactivation and HPV-speciﬁc cell-cycle exit and/or
apoptosis [15]. Furthermore, both radiation [16]a n dm a n y
forms of chemotherapy [17]m o r ee ﬀectively kill cervical
cancer cells in which E6 and/or E7 expression is attenuated.
We have identiﬁed an endogenous human cytokine, LIF,
which is capable of directly and drastically repressing E62 Infectious Diseases in Obstetrics and Gynecology
and E7 expression in cultured cervical squamous carcinoma
cells and reducing or halting proliferation of such cells.
As a phase I-tested[18] pharmaceutical with little toxicity,
LIF is a promising candidate for the treatment of CIN,
cervical carcinoma, and other HPV-dependent pathologies,
either independently or in combination with cytotoxic
chemotherapy.
2.Materialsand Methods
2.1. Cell Culture. Human cervical cancer lines CaSki and
SiHa were purchased from the American Type Culture
Collection and cultured in Dulbecco’s Modiﬁed Eagle
Medium(DMEM) supplementedwith 100IU/mL penicillin,
100μg/mL streptomycin, and (except where noted) 10% fetal
calf serum at 5% CO2. In several assays, where noted, serum
was reduced or removed entirely.
2.2.Drugs. LIF(Millipore)wasstoredinphosphate-buﬀered
saline(PBS)at4◦CanddilutedinDMEMpriortouse.TNFa,
IL-6, and EGF (Biosource, Invitrogen) were dissolved in PBS
with BSA, stored at −20◦C, and diluted in DMEM or RPMI
prior to use.
2.3.GenerationofanHPV-16 ReporterCell Line. Thecervical
cancer cell line SiHa was chosen because of its relatively
high native HPV-16 LCR activity and signiﬁcant expression
of the E6 and E7 genes, similar to that in a progressing
dysplastic lesion. The cells were transfected with the plasmid
pLCRGLuc, which contains a complete HPV-16 LCR cloned
upstream of a secreted Gaussia luciferase gene as well as a
neomycin resistance gene driven by an SV40 promoter. Cells
were selected with 400μg/mL G418 for seven days.
2.4. Cell Proliferation Assay. Cell proliferation was deter-
mined by CellTiter 96 (Promega) (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells
were seeded at 5,000 per well in a 96-well plate and treated
with the speciﬁed cytokines. After the indicated periods, the
cells were incubated according to the manufacturer’s proto-
col with the MTT labeling solution for 4h, then with the
solubilization/stop solution overnight. Reduction of MTT
to MTT-formazan, indicating cellular metabolic activity,
was quantiﬁed by measurement of absorbance at 570nm
on a SpectraMax microplate reader (Molecular Devices)
and background absorbance of 650nm was subtracted. All
experimentsweredoneintriplicateorhighermultiplicatefor
statistical power.
2.5. Luciferase Assays. For ﬁreﬂy luciferase, cells were seeded
in 12-well plates at a density of 50,000/well and transfected
with the indicated reporter plasmids using SuperFect (QIA-
GEN, Alameda, Calif, USA) according to manufacturer’s
instructions. After 18 hours, medium was replaced and the
cells treated with the indicated stimuli for the time periods
noted. Luciferase was released from cells using the supplied
lysis buﬀer and luminescence measured using luciferase
substrate (New England Biolabs, Ipswich, Mass, USA).
For Gaussia luciferase, SiHa-LCR-gLuc cells were seeded
in 96-well plates at a density of ∼5,000/well and treated as
indicated. Following incubation, 20 (micro)L of supernatant
from each well was transferred to a new plate. Gaussia
luciferase reagent (New England Biolabs) was added and the
luminescence measured for 5 seconds.
2.6. Quantitative Real-Time PCR. In order to directly mea-
sure the expression of E6 and E7 mRNA, we designed
primer sets and probes speciﬁc to the E6 gene and the
E7 gene; oligonucleotides were synthesized by Euroﬁns
MWG Operon (Huntsville, AL). Primer sequences for the
E6 mRNA were 5 -CAAACCGTTGTGTGATTTGTTAAT-
TA-3  and 5 -GCTTTTTGTCCAGATGTCTTTGC-3  and
the probe was 5 [6-FAM]TGTATTAACTGTCAAAAGCCA-
CTGTGTCCTGAAGAA[TAMRA-6-FAM]-3 , correspond-
ing to nucleotides 382-444. For E7, primer sequences
were 5 -GTGACTCTACGCTTCGGTTGT-3  and 5 -GCC-
CATTAACAGGTGTTCCA-3  and the probe sequence
was 5 [6-FAM]CGTACAAAGCACACACGTAGACATTCG-
TAC[BHQ1a-6FAM]-3 , corresponding to nucleotides 743–
794 (or 743–1955 in the SiHa variant). Following experi-
mental treatments, RNA was harvested using the RNeasy
kit (Qiagen), quantiﬁed by spectrophotometry (NanoDrop
8000, Thermo Scientiﬁc), equal quantities ampliﬁed using
the TaqMan kit (Applied Biosystems) according to the
standard protocol (qv) on an ABI Prism 7700. We estimated
the quantity of HPV mRNA relative to β-actin mRNA using
the 2−ΔΔCT method [19].
2.7. Intracellular Phosphospeciﬁc Flow Cytometry. Trypsi-
nized cells (10,000 for each timepoint) were ﬁxed with
1.2%paraformaldehydeatroomtemperaturefor10minutes,
rinsed with PBS containing 1% BSA, permeabilized in
PBS/90% ice-cold methanol, and stored at −20◦Co v e r n i g h t
orforupto2weeks.Priortostaining,cellswerewashedtwice
in PBS containing 1% BSA.Cells were stained on ice with the
indicated antibodies for 30 minutes at 4◦C and analyzed on a
FC500 ﬂow cytometer (Beckman-Coulter). Further analysis
was performed using cytobank (http://www.cytobank.org/).
2.8. Statistics. Statistical analysis (unpaired t-test) was per-
formedusingGraphPad software (graphpad.com)asneeded.
P values indicating statistical signiﬁcance are represented by
as i n g l e( P<. 1) or double asterisk (P<. 05) on the ﬁgures.
3.Resultsand Discussion
3.1. LIF Inhibits HPV-16 LCR-Driven Transcription. In this
study, we compared the transcriptional activity of the HPV-
16 LCR in untreated cervical SiHa cells and cells treated
with various cytokines. The IL-6 superfamily member LIF
reduced HPV-16 LCR expression by approximately 60% in
a time- and dose-dependent manner (Figure 1(a)). In order
to verify that the observed decrease in LCR transcription is
functionally signiﬁcant and not an artifact of the reporter
system, we examined the eﬀect of LIF on mRNA expression
by quantitative real-time PCR. CaSki cervical cancer cells
were treated with 1ng/mL or 10ng/mL of LIF or with PBSInfectious Diseases in Obstetrics and Gynecology 3
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Figure 1: (a) Luciferase expression in LIF-treated and untreated SiHa pGLuc cells. (b) CaSki cells were treated with the indicated
concentrations of LIF for 24 hours. Quantitative real-time PCR was performed as described. Error bars represent standard error of the
mean. (c) CaSki and SiHa cells were treated with the indicated concentrations of LIF for 72 hours. Quantitation of E6 relative to β-actin is
represented in arbitrary units. Error bars represent standard error of the mean. Asterisks represent signiﬁcance (∗P<. 1, ∗∗P<. 05).
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was signiﬁcantly reduced over this time course, initially in
a dose-dependent manner (Figure 1(b)), although at three
days, cells treated with the low or high concentrations of
LIF showed similar inhibition ofE7; E6 inhibition followed a
similar trend (Figure 1(c)).
3.2. Induction of Phosphorylation of STAT3 In Cervical Cancer
Cells. Because LIF is known to activate members of the
JAK-STAT pathway, typically JAK1 and STAT3 in a cell-
speciﬁc manner through binding to the heterodimeric LIFR-
gp130 receptor [19, 20], we evaluated the eﬀect of LIF on
STAT3 activation in SiHa cells. STAT3 is a multifunctional
signaling molecule generally considered to promote survival,
proliferation, and tumorigenesis but can also be involved in
the initiation of senescence and programmed cell death [21].
Followingtreatment with LIF,STAT3 was phosphorylated on
tyrosine residue 705, indicative of activation, in a transient
fashion (Figure 2(a)).
To determine if the observed phosphorylation was
accompanied by transcriptional activation, we used the
reporter plasmid 4xM67 pTATA TK-Luc; SiHa cells were
transfected; after 18 hours, cells were treated with 10ng/mL
LIF or PBS. After six hours, cells were lysed and analyzed
as described. The activity of the reporter plasmid was 1.8-
fold higher in LIF-treated cells than in untreated cells
(Figure 2(b)).
3.3. Proliferation of HPV-Transformed Cells. CaSki cells were
seeded in 96-well plates at a density of ∼5000/well in growth
medium. After the cells attached (∼6h o u r s ) ,t h em e d i u m
was replaced with serum-free medium containing LIF, the
LCR-inhibiting cytokines IL-6 or EGF [22], or PBS. After 40
hours the proliferation of cells was measured using the MTT4 Infectious Diseases in Obstetrics and Gynecology
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Figure 2: (a) SiHa cells were stimulated with LIF (10ng/mL) for the times indicated (in minutes), and the level of phospho-STAT3(y705)
measured.STAT3istransientlyphosphorylatedfollowingstimulationwithLIFwithin60minutes,returning tobaselinelevelby 120minutes.
Histograms are colored according to the log10-fold increase in mean ﬂuorescence intensity relative to unstimulated cells. (b) CaSki cells
transfected with a STAT3 reporter plasmid were treated with 50ng/mL LIF for 6 hours prior to assay. The increase in relative light units is
shown. Error bars represent standard error of the mean. Asterisks represent signiﬁcance (∗∗P<. 05).
∗∗
∗∗
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Untreated LIF EGF IL-6
Untreated
LIF
EGF
IL-6
Figure 3: CaSki cells grown for 40 hours in the presence of the
indicated agents were assayed by MTT for proliferation/metabolic
activity. EGF and IL-6 enhanced cell number, while LIF inhibited
proliferation. Error bars represent standard error of the mean.
Asterisks represent signiﬁcance (∗∗P<. 05).
assay described earlier. As expected, EGF promoted the
proliferation of the cells relative to untreated cells. The LIF-
treated cells, however, proliferated much less rapidly, only
reaching a ﬁnal population density approximately half that
of untreated cells (Figure 3).
Treatment of HPV-16-transformed cervical cancer cells
withLIFinhibitstheviralLCR,causingasubstantialdecrease
in the abundance of the E6/E7 mRNA. This inhibition is
concomitant with reduced proliferation. The absence of a
signiﬁcant loss of membrane asymmetry (data not shown)
leads us to reason that LIF-treated cells undergo cell-cycle
arrest rather than apoptosis. Whether this is speciﬁc to the
cell lines used or would generally be the case in HPV-
transformed cells remains to be seen.
It has been postulated that high-level transcription
of HPV is normally repressed by a cytokine-mediated
intercellular control mechanism and that disruption of this
is necessary for malignant transformation [23]. Native or
exogenous cytokines, by activating or inactivating signaling
pathways subverted by HPV, could allow the cell to revert
from the malignant state back toward diﬀerentiation or
programmed cell death. Severalcytokines,includingTGF-β1
and IL-4,are known tomodulate transcription of HPV atthe
level of the LCR though in some cases, this is insuﬃcient for
reversal of the transformed phenotype. While IL-6 exposure
represses the transcriptional activity of the HPV LCR [24], it
nonetheless induces increased proliferation in both normal
and cancerous cervical cells [25]. Exposure to TGF-β1,
however, results in the downregulation of HPV oncogenes
[26] and inhibits growth of early but not late HPV-
immortalized cells [27]. Notably, TGF-β1 fails to induce the
downregulationofE6andE7inSiHacellsanddoesnotcause
these cells to arrest. The interferons, particularly IFN-a2 andInfectious Diseases in Obstetrics and Gynecology 5
IFN-g, are potent inhibitors of HPV and have displayed
some promise as therapeutics for HPV infection, but the
actualclinicaleﬀectivenesshas beeninconsistent. Interferon-
responsive elements which enhance transcriptional activity
have been identiﬁed in the LCR [28], and late passage or
malignantly transformed cells generally do not respond to
IFN-γ [29] or other inhibitory cytokines [23].
LIF’s role in promoting the diﬀerentiation of lympho-
cytes into anti-inﬂammatory regulatory cells [30]m a yb e
causeforconcern,as thepresence ofsuchimmunoregulatory
cells has been found to support tumor tolerance and
progression, contributing to migration and metastasis of
tumor cells [31].
However, this potential increase in immune evasion is
likely outweighed by the loss of viral oncogene expression.
Additionally, LIF has demonstrated potent anti-HIV activity
[32], most likely due to its role as a suppressor of inﬂamma-
tion, suggesting its use in HIV-seropositive CIN and cervical
cancer patients would have multiple therapeutic beneﬁts.
4.Conclusions
Figure 1shows the eﬀectofLIFon theexpression ofthe HPV
LCR and on two oncogenes controlled by this promoter. In
two unrelated cell lines, both HPV-16 transformed, LCR-
dependent transcription was signiﬁcantly inhibited by LIF.
Other means of achieving similar reductions in HPV mRNA,
such as siRNA or peptide aptamer transfection, are observed
to be suﬃcient to inhibit the growth of cervical cancer cells
in vitro and in vivo. As shown in Figure 2,L I Fi n c r e a s e st h e
activity of the already constitutively active STAT3 in cervical
cancer cells. While the signiﬁcance of this activation is as
yet uncertain, the STAT3 pathway appears to be involved
in HPV-16 pathogenesis [33]a n dm a yb eat a r g e tf o r
therapeutic intervention. LIF strongly inhibits the growth of
HPV-16 transformed cervical cells and appears to act at least
in part through an HPV-speciﬁc mechanism.
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